Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Glioblastoma × abemaciclib × Clear all

Phase

Status

Recruiting 2 Completed 2 Withdrawn 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Solid Tumor 1 Prostatic Neoplasms 1 Glioma 1 Glioblastoma 1 Breast Cancer Female 1 Brain Neoplasms 1

Interventions

Temozolomide 8 Magnetic Resonance Spectroscopy 7 Bevacizumab 7 Radiotherapy 3 Radiation 3 Lomustine 3 pembrolizumab 2 dexamethasone acetate 2 TIC10 compound 2 Surgical Procedures, Operative 2 Sunitinib 2 Standard of Care 2 Specimen Handling 2 Radiosurgery 2 Irinotecan 2 Dexamethasone 2 Carmustine 2 Carboplatin 2 Calcium Dobesilate 2 Axitinib 2 Aminolevulinic Acid 2 vocimagene amiretrorepvec 1 tandutinib 1 poly ICLC 1 pazopanib 1 niraparib 1 keyhole-limpet hemocyanin 1 gallium Ga 68 dotatate 1 fluciclovine F-18 1 ficlatuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04118036 2025-08-11

Abemaciclib + Pembrolizumab In Glioblastoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡